Affinity DataEC50: 1.30E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 2.00E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 1.30E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 2.00E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 700nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 700nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 1.00E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 1.70E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 3.80E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 7.60E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 2.00E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 600nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 1.20E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 2.50E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 4.00E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 2.00E+3nMAssay Description:Concentration at which one-half the maximum Low density lipoprotein receptor up-regulation is observed in HepG2 cellsMore data for this Ligand-Target Pair
Affinity DataEC50: 7.00E+3nMAssay Description:Concentration at which one-half of the maximum Low density lipoprotein receptor is upregulated in HepG2 cellsMore data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Human)
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
